• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation, October 18, 2012 - Q-Pan

 

Submission Type: BLA    Submission ID: 125419/0    Office: OVRR
Product:
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Applicant:
ID Biomedical Corporation of Quebec
Telecon Date/Time: 18-Oct-2012 10:12 AM        Initiated by FDA? Yes
Telephone Number: michael.p.schwartz@gsk.com; robert.d.brobst@gsk.com
Communication Categorie(s):
1. Information Request
 
Author: KIRK PRUTZMAN
Telecon Summary:
IR Regarding Anti-Microbial Effectiveness Testing
FDA Participants: KIRK PRUTZMAN, CARMEN COLLAZO, JEREMY WALLY
Non-FDA Participants: MICHAEL SCHWARTZ, ROBERT BROBST
Trans-BLA Group: No
 
Related STNs: None
Related PMCs: None
Telecon Body:
From:                    Prutzman, Kirk C
Sent:                      Thursday, October 18, 2012 10:12 AM
To:                         'Michael Schwartz'; Robert Brobst
Cc:                         Collazo, Carmen; Wally, Jeremy
Subject:                 STN 125419 - Qpan - Information Request
Dear Drs. Schwartz and Brobst,
We have the following request for additional information regarding Anti-Microbial Effectiveness Testing for STN 125419 (Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted):
1.     For preservative efficacy in 3.2.P.2.5, Pharmaceutical Development, Microbial Attributes, the protocol provided does not provide enough detail regarding the procedure. Please submit a detailed SOP used for anti-microbial effectiveness testing to include the amount of sample removed and tested at each time point, procedure for-------(b)(4)------------ including type of agar, temperature and incubation duration for each ---(b)(4)---.
 
Please submit your responses in an amendment to the BLA submission.
If you have any questions about this communication, please contact Kirk Prutzman, Carmen M. Collazo, or Jeremy Wally.
Regards,
 
Kirk Prutzman, PhD
Food and Drug Administration
Primary Reviewer/Regulatory Project Manager
CBER/OVRR/DVRPA/CMC3
1451 Rockville Pike (WOC2)
Room 2241
HFM-481
Rockville, MD 20857
Phone: (301) 796-2640